Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in ALK-positive Advanced NSCLC
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Alunbrig
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.
View on EMAFabry Disease
Type 2 Diabetes Mellitus
Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Disease
Hypertension